Voriconazole treatment for less-common, emerging, or refractory fungal infections

John R. Perfect, Kieren A. Marr, Thomas J. Walsh, Richard N. Greenberg, Bertrand DuPont, Juliàn De La Torre-Cisneros, Gudrun Just-Nübling, Haran T. Schlamm, Irja Lutsar, Ana Espinel-Ingroff, Elizabeth Johnson

Research output: Contribution to journalArticlepeer-review

632 Scopus citations


Treatments for invasive fungal infections remain unsatisfactory. We evaluated the efficacy, tolerability, and safety of voriconazole as salvage treatment for 273 patients with refractory and intolerant-to-treatment fungal infections and as primary treatment for 28 patients with infections for which there is no approved therapy. Voriconazole was associated with satisfactory global responses in 50% of the overall cohort; specifically, successful outcomes were observed in 47% of patients whose infections failed to respond to previous antifungal therapy and in 68% of patients whose infections have no approved antifungal therapy. In this population at high risk for treatment failure, the efficacy rates for voriconazole were 43.7% for aspergillosis, 57.5% for candidiasis, 38.9% for cryptococcosis, 45.5% for fusariosis, and 30% for scedosporiosis. Voriconazole was well tolerated, and treatment-related discontinuations of therapy or dose reductions occurred for <10% of patients. Voriconazole is an effective and well-tolerated treatment for refractory or less-common invasive fungal infections.

Original languageEnglish
Pages (from-to)1122-1131
Number of pages10
JournalClinical Infectious Diseases
Issue number9
StatePublished - May 1 2003

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases


Dive into the research topics of 'Voriconazole treatment for less-common, emerging, or refractory fungal infections'. Together they form a unique fingerprint.

Cite this